Comparing Bavarian Nordic A/S (OTCMKTS:BVNRY) and Cognition Therapeutics (NASDAQ:CGTX)

Cognition Therapeutics (NASDAQ:CGTXGet Free Report) and Bavarian Nordic A/S (OTCMKTS:BVNRYGet Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Cognition Therapeutics and Bavarian Nordic A/S, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cognition Therapeutics 0 0 1 0 3.00
Bavarian Nordic A/S 0 0 0 0 N/A

Cognition Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 155.32%. Given Cognition Therapeutics’ higher probable upside, equities research analysts plainly believe Cognition Therapeutics is more favorable than Bavarian Nordic A/S.

Profitability

This table compares Cognition Therapeutics and Bavarian Nordic A/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cognition Therapeutics N/A -65.53% -51.07%
Bavarian Nordic A/S 12.21% 0.06% 9.49%

Insider and Institutional Ownership

23.4% of Cognition Therapeutics shares are held by institutional investors. 23.8% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Cognition Therapeutics and Bavarian Nordic A/S’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cognition Therapeutics N/A N/A -$21.40 million ($0.79) -2.97
Bavarian Nordic A/S $446.20 million 3.97 -$49.19 million $0.49 15.43

Cognition Therapeutics has higher earnings, but lower revenue than Bavarian Nordic A/S. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Bavarian Nordic A/S, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cognition Therapeutics has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Bavarian Nordic A/S has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.

About Cognition Therapeutics

(Get Free Report)

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.

About Bavarian Nordic A/S

(Get Free Report)

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Receive News & Ratings for Cognition Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognition Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.